{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T10:06:22Z","timestamp":1790676382941,"version":"4.1.0"},"reference-count":41,"publisher":"Oxford University Press (OUP)","issue":"2","license":[{"start":{"date-parts":[[2024,1,18]],"date-time":"2024-01-18T00:00:00Z","timestamp":1705536000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"},{"start":{"date-parts":[[2024,1,18]],"date-time":"2024-01-18T00:00:00Z","timestamp":1705536000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2024,2,1]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Aims<\/jats:title>\n                    <jats:p>The therapeutic mechanism of sodium\u2013glucose cotransporter 2 inhibitors (SGLT2i) on left cardiac remodelling in patients with heart failure with reduced ejection fraction (HFrEF) is not well-established. This study meta-analysed the impact of SGLT2i on left cardiac structure and function in patients with HFrEF.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods and results<\/jats:title>\n                    <jats:p>Online databases were queried up to April 2023 for trials reporting indicators of left cardiac structure and function in patients with HFrEF treated with SGLT2i. Data from studies were pooled using a random-effects model to derive weighted mean differences (WMDs) and 95% confidence intervals (CIs). Six trials were included (n\u2009=\u2009555). Compared with control, SGLT2i significantly improved left ventricular end-diastolic volume (LVEDV; WMD: \u221217.07\u2009ml [\u221223.84, \u221210.31]; p\u2009&amp;lt;\u20090.001), LVEDV index (WMD: \u22125.62\u2009ml\/m2 [\u221210.28, \u22120.97]; p\u2009=\u20090.02), left ventricular end-systolic volume (LVESV; WMD: \u221215.63\u2009ml [\u221226.15, \u22125.12]; p\u2009=\u20090.004), LVESV index (WMD: \u22126.90\u2009ml\/m2 [\u221210.68, \u22123.11]; p\u2009=\u20090.001), left ventricular ejection fraction (WMD: 2.71% [0.70, 4.72]; p\u2009=\u20090.008), and left atrial volume index (WMD: \u22122.19\u2009ml\/m2 [\u22124.26, \u22120.11]; p\u2009=\u20090.04) in patients with HFrEF. SGLT2i use was associated with a non-significant trend towards a reduction in left ventricular mass index (WMD: \u22126.25\u2009g\/m2 [\u221212.79, 0.28]; p\u2009=\u20090.06). No significant impact on left ventricular global longitudinal strain was noted (WMD: 0.21% [\u22120.25, 0.67]; p\u2009=\u20090.38).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Sodium\u2013glucose cotransporter 2 inhibitors improve cardiac structure and function in patients with HFrEF.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1002\/ejhf.3129","type":"journal-article","created":{"date-parts":[[2024,1,18]],"date-time":"2024-01-18T10:10:55Z","timestamp":1705572655000},"page":"373-382","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":38,"title":["The Effect of Sodium\u2013Glucose Cotransporter 2 Inhibitors on Left Cardiac Remodelling in Heart Failure with Reduced Ejection Fraction: Systematic Review and Meta-Analysis"],"prefix":"10.1093","volume":"26","author":[{"given":"Muhammad Shariq","family":"Usman","sequence":"first","affiliation":[{"name":"Department of Medicine, UT Southwestern Medical Center , Dallas, TX ,","place":["USA"]},{"name":"Department of Medicine, Parkland Health and Hospital System , Dallas, TX ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James L.","family":"Januzzi","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Massachusetts General Hospital , Boston, MA ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefan D.","family":"Anker","sequence":"additional","affiliation":[{"name":"Department of Cardiology (CVK) and Berlin Institute of Health Center for Regenerative Therapies, German Centre for Cardiovascular Research, Partner Site Berlin, Charit\u00e9\u2014Universit\u00e4tsmedizin Berlin , Berlin ,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ali","family":"Salman","sequence":"additional","affiliation":[{"name":"Department of Medicine, Dow University of Health Sciences , Karachi ,","place":["Pakistan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Puja B.","family":"Parikh","sequence":"additional","affiliation":[{"name":"Department of Medicine, Stony Brook University Renaissance School of Medicine , Stony Brook, NY ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marianna","family":"Adamo","sequence":"additional","affiliation":[{"name":"Cardiology Unit and Cardiac Catheterization Laboratory, ASST Spedali Civili di Brescia, Department of Medical and Surgical Specialties, Radiological Sciences and Public Health, University of Brescia , Brescia ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gerasimos","family":"Filippatos","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Attikon University Hospital, School of Medicine, National and Kapodistrian University of Athens , Athens ,","place":["Greece"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muhammad Shahzeb","family":"Khan","sequence":"additional","affiliation":[{"name":"Division of Cardiology, Duke University Medical Center , Durham, NC ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anuradha","family":"Lala","sequence":"additional","affiliation":[{"name":"Zena and Michael A. Wiener Cardiovascular Institute and Department of Population Health Science and Policy , New York, NY ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Subodh","family":"Verma","sequence":"additional","affiliation":[{"name":"Division of Cardiac Surgery, Li Ka Shing Knowledge Institute of St. Michael's Hospital, Departments of Surgery and Pharmacology and Toxicology, University of Toronto , Toronto, ON ,","place":["Canada"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco","family":"Metra","sequence":"additional","affiliation":[{"name":"Cardiology Unit and Cardiac Catheterization Laboratory, ASST Spedali Civili di Brescia, Department of Medical and Surgical Specialties, Radiological Sciences and Public Health, University of Brescia , Brescia ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Javed","family":"Butler","sequence":"additional","affiliation":[{"name":"Baylor Scott and White Research Institute, Baylor Scott and White Health , Dallas, TX ,","place":["USA"]},{"name":"Department of Medicine, University of Mississippi Medical Center , Jackson, MS ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2024,1,18]]},"reference":[{"key":"2026010913041688500_ejhf3129-bib-0001","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1007\/s13300-014-0089-4","article-title":"Sodium glucose Co-Transporter-2 (SGLT2) inhibitors: A review of their basic and clinical pharmacology","volume":"5","author":"Kalra","year":"2014","journal-title":"Diabetes Ther"},{"key":"2026010913041688500_ejhf3129-bib-0002","doi-asserted-by":"crossref","first-page":"2117","DOI":"10.1056\/NEJMoa1504720","article-title":"Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes","volume":"373","author":"Zinman","year":"2015","journal-title":"N Engl J Med"},{"key":"2026010913041688500_ejhf3129-bib-0003","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1056\/NEJMoa1611925","article-title":"Canagliflozin and cardiovascular and renal events in type 2 diabetes","volume":"377","author":"Neal","year":"2017","journal-title":"N Engl J Med"},{"key":"2026010913041688500_ejhf3129-bib-0004","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1056\/NEJMoa1812389","article-title":"Dapagliflozin and cardiovascular outcomes in type 2 diabetes","volume":"380","author":"Wiviott","year":"2019","journal-title":"N Engl J Med"},{"key":"2026010913041688500_ejhf3129-bib-0005","doi-asserted-by":"crossref","first-page":"1425","DOI":"10.1056\/NEJMoa2004967","article-title":"Cardiovascular outcomes with ertugliflozin in type 2 diabetes","volume":"383","author":"Cannon","year":"2020","journal-title":"N Engl J Med"},{"key":"2026010913041688500_ejhf3129-bib-0006","doi-asserted-by":"crossref","first-page":"1995","DOI":"10.1056\/NEJMoa1911303","article-title":"Dapagliflozin in patients with heart failure and reduced ejection fraction","volume":"381","author":"McMurray","year":"2019","journal-title":"N Engl J Med"},{"key":"2026010913041688500_ejhf3129-bib-0007","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.1056\/NEJMoa2022190","article-title":"Cardiovascular and renal outcomes with empagliflozin in heart failure","volume":"383","author":"Packer","year":"2020","journal-title":"N Engl J Med"},{"key":"2026010913041688500_ejhf3129-bib-0008","doi-asserted-by":"crossref","first-page":"1353","DOI":"10.1001\/jama.2020.1906","article-title":"Effect of dapagliflozin on worsening heart failure and cardiovascular death in patients with heart failure with and without diabetes","volume":"323","author":"Petrie","year":"2020","journal-title":"JAMA"},{"key":"2026010913041688500_ejhf3129-bib-0009","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1016\/j.jacc.2010.05.011","article-title":"Quantitative evaluation of drug or device effects on ventricular remodeling as predictors of therapeutic effects on mortality in patients with heart failure and reduced ejection fraction: A meta-analytic approach","volume":"56","author":"Kramer","year":"2010","journal-title":"J Am Coll Cardiol"},{"key":"2026010913041688500_ejhf3129-bib-0010","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/j.jchf.2022.09.009","article-title":"Prediction of left ventricular ejection fraction change following treatment with sacubitril\/valsartan","volume":"11","author":"Mohebi","year":"2023","journal-title":"JACC Heart Fail"},{"key":"2026010913041688500_ejhf3129-bib-0011","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1186\/s12933-019-0938-6","article-title":"Lessons learned from the DAPA-HF trial concerning the mechanisms of benefit of SGLT2 inhibitors on heart failure events in the context of other large-scale trials nearing completion","volume":"18","author":"Packer","year":"2019","journal-title":"Cardiovasc Diabetol"},{"key":"2026010913041688500_ejhf3129-bib-0012","doi-asserted-by":"crossref","first-page":"1961","DOI":"10.1093\/eurjpc\/zwab173","article-title":"Effect of sodium-glucose cotransporter-2 inhibitors on cardiac remodelling: A systematic review and meta-analysis","volume":"28","author":"Zhang","year":"2022","journal-title":"Eur J Prev Cardiol"},{"key":"2026010913041688500_ejhf3129-bib-0013","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.ejim.2023.04.002","article-title":"The effect of sodium-glucose cotransporter-2 inhibitors on cardiac structure remodeling and function: A meta-analysis of randomized controlled trials","volume":"114","author":"Fan","year":"2023","journal-title":"Eur J Intern Med"},{"key":"2026010913041688500_ejhf3129-bib-0014","doi-asserted-by":"crossref","first-page":"4693","DOI":"10.1002\/ehf2.13645","article-title":"SGLT2 inhibitors and cardiac remodelling: A systematic review and meta-analysis of randomized cardiac magnetic resonance imaging trials","volume":"8","author":"Dhingra","year":"2021","journal-title":"ESC Heart Fail"},{"key":"2026010913041688500_ejhf3129-bib-0015","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1186\/s12933-023-01970-w","article-title":"Left ventricular remodeling response to SGLT2 inhibitors in heart failure: An updated meta-analysis of randomized controlled studies","volume":"22","author":"Carluccio","year":"2023","journal-title":"Cardiovasc Diabetol"},{"key":"2026010913041688500_ejhf3129-bib-0016","doi-asserted-by":"crossref","DOI":"10.1136\/bmj.b2700","article-title":"The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: Explanation and elaboration","volume":"339","author":"Liberati","year":"2009","journal-title":"BMJ"},{"key":"2026010913041688500_ejhf3129-bib-0017","volume-title":"Cochrane Handbook for Systematic Reviews of Interventions","author":"Higgins","year":"2020","edition":"Second ed."},{"key":"2026010913041688500_ejhf3129-bib-0018","article-title":"RoB 2: A revised tool for assessing risk of bias in randomised trials","volume":"366","author":"Sterne","year":"2019","journal-title":"BMJ"},{"key":"2026010913041688500_ejhf3129-bib-0019","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1002\/9780470743386.ch4","volume-title":"Introduction to Meta-analysis","author":"Borenstein","year":"2009"},{"key":"2026010913041688500_ejhf3129-bib-0020","doi-asserted-by":"crossref","DOI":"10.4135\/9781412984997","volume-title":"Meta-Analytic Procedures for Social Research","author":"Rosenthal","year":"1991"},{"key":"2026010913041688500_ejhf3129-bib-0021","doi-asserted-by":"crossref","first-page":"2520","DOI":"10.1177\/0962280219889080","article-title":"Estimating the sample mean and standard deviation from commonly reported quantiles in meta-analysis","volume":"29","author":"McGrath","year":"2020","journal-title":"Stat Methods Med Res"},{"key":"2026010913041688500_ejhf3129-bib-0022","doi-asserted-by":"crossref","first-page":"1816","DOI":"10.1002\/ejhf.2560","article-title":"Short-term effects of dapagliflozin on maximal functional capacity in heart failure with reduced ejection fraction (DAPA-VO2): A randomized clinical trial","volume":"24","author":"Palau","year":"2022","journal-title":"Eur J Heart Fail"},{"key":"2026010913041688500_ejhf3129-bib-0023","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1161\/CIRCULATIONAHA.120.052186","article-title":"Effect of empagliflozin on left ventricular volumes in patients with type 2 diabetes, or prediabetes, and heart failure with reduced ejection fraction (SUGAR-DM-HF)","volume":"143","author":"Lee","year":"2021","journal-title":"Circulation"},{"key":"2026010913041688500_ejhf3129-bib-0024","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1016\/j.jacc.2020.11.008","article-title":"Randomized trial of empagliflozin in nondiabetic patients with heart failure and reduced ejection fraction","volume":"77","author":"Santos-Gallego","year":"2021","journal-title":"J Am Coll Cardiol"},{"key":"2026010913041688500_ejhf3129-bib-0025","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1001\/jamacardio.2020.6827","article-title":"Associations of empagliflozin with left ventricular volumes, mass, and function in patients with heart failure and reduced ejection fraction: A substudy of the Empire HF randomized clinical trial","volume":"6","author":"Omar","year":"2021","journal-title":"JAMA Cardiol"},{"key":"2026010913041688500_ejhf3129-bib-0026","doi-asserted-by":"crossref","DOI":"10.1002\/dmrr.3335","article-title":"The effects of canagliflozin compared to sitagliptin on cardiorespiratory fitness in type 2 diabetes mellitus and heart failure with reduced ejection fraction: The CANA-HF study","volume":"36","author":"Carbone","year":"2020","journal-title":"Diabetes Metab Res Rev"},{"key":"2026010913041688500_ejhf3129-bib-0027","doi-asserted-by":"crossref","first-page":"1585","DOI":"10.1002\/ehf2.12707","article-title":"Effects of canagliflozin in patients with type 2 diabetes and chronic heart failure: A randomized trial (CANDLE)","volume":"7","author":"Tanaka","year":"2020","journal-title":"ESC Heart Fail"},{"key":"2026010913041688500_ejhf3129-bib-0028","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1038\/nrcardio.2011.172","article-title":"Reverse remodeling in heart failure \u2013 Mechanisms and therapeutic opportunities","volume":"9","author":"Koitabashi","year":"2011","journal-title":"Nat Rev Cardiol"},{"key":"2026010913041688500_ejhf3129-bib-0029","first-page":"e294","article-title":"Type 2 diabetes mellitus and heart failure: A scientific statement from the American Heart Association and the Heart Failure Society of America: This statement does not represent an update of the 2017 ACC\/AHA\/HFSA heart failure guideline update","volume":"2019","author":"Dunlay","journal-title":"Circulation"},{"key":"2026010913041688500_ejhf3129-bib-0030","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1002\/ejhf.2493","article-title":"Cardiac remodelling \u2013 Part 1: From cells and tissues to circulating biomarkers. A review from the Study Group on Biomarkers of the Heart Failure Association of the European Society of Cardiology","volume":"24","author":"Gonz\u00e1lez","year":"2022","journal-title":"Eur J Heart Fail"},{"key":"2026010913041688500_ejhf3129-bib-0031","doi-asserted-by":"crossref","first-page":"782","DOI":"10.1016\/j.jchf.2019.06.004","article-title":"Imaging, biomarker, and clinical predictors of cardiac remodeling in heart failure with reduced ejection fraction","volume":"7","author":"Aimo","year":"2019","journal-title":"JACC Heart Fail"},{"key":"2026010913041688500_ejhf3129-bib-0032","doi-asserted-by":"crossref","first-page":"944","DOI":"10.1007\/s12265-022-10220-5","article-title":"Sodium-glucose cotransporter 2 inhibitors and cardiac remodeling","volume":"15","author":"Salah","year":"2022","journal-title":"J Cardiovasc Trans Res"},{"key":"2026010913041688500_ejhf3129-bib-0033","doi-asserted-by":"crossref","first-page":"862","DOI":"10.1002\/ejhf.1473","article-title":"Sodium-glucose co-transporter 2 inhibition with empagliflozin improves cardiac function in non-diabetic rats with left ventricular dysfunction after myocardial infarction","volume":"21","author":"Yurista","year":"2019","journal-title":"Eur J Heart Fail"},{"key":"2026010913041688500_ejhf3129-bib-0034","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1016\/j.jacbts.2020.02.004","article-title":"Mechanisms of cardiovascular benefits of sodium glucose co-transporter 2 (SGLT2) inhibitors: A state-of-the-art review","volume":"5","author":"Lopaschuk","year":"2020","journal-title":"JACC Basic Transl Sci"},{"key":"2026010913041688500_ejhf3129-bib-0035","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1161\/CIRCULATIONAHA.122.061732","article-title":"Critical reanalysis of the mechanisms underlying the cardiorenal benefits of SGLT2 inhibitors and reaffirmation of the nutrient deprivation signaling\/autophagy hypothesis","volume":"146","author":"Packer","year":"2022","journal-title":"Circulation"},{"key":"2026010913041688500_ejhf3129-bib-0036","doi-asserted-by":"crossref","first-page":"1834","DOI":"10.1016\/j.jacc.2008.08.027","article-title":"Randomized trial of cardiac resynchronization in mildly symptomatic heart failure patients and in asymptomatic patients with left ventricular dysfunction and previous heart failure symptoms","volume":"52","author":"Linde","year":"2008","journal-title":"J Am Coll Cardiol"},{"key":"2026010913041688500_ejhf3129-bib-0037","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1161\/01.CIR.0000108928.25690.94","article-title":"Effects of carvedilol on left ventricular remodeling after acute myocardial infarction: The CAPRICORN Echo Substudy","volume":"109","author":"Doughty","year":"2004","journal-title":"Circulation"},{"key":"2026010913041688500_ejhf3129-bib-0038","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1161\/01.CIR.86.2.431","article-title":"Effects of the angiotensin converting enzyme inhibitor enalapril on the long-term progression of left ventricular dysfunction in patients with heart failure. SOLVD Investigators","volume":"86","author":"Konstam","year":"1992","journal-title":"Circulation"},{"key":"2026010913041688500_ejhf3129-bib-0039","doi-asserted-by":"crossref","first-page":"1292","DOI":"10.1016\/j.amjcard.2010.06.052","article-title":"Effect of spironolactone on left ventricular ejection fraction and volumes in patients with class I or II heart failure","volume":"106","author":"Vizzardi","year":"2010","journal-title":"Am J Cardiol"},{"key":"2026010913041688500_ejhf3129-bib-0040","doi-asserted-by":"crossref","first-page":"1085","DOI":"10.1001\/jama.2019.12821","article-title":"Association of change in N-terminal pro-B-type natriuretic peptide following initiation of sacubitril-valsartan treatment with cardiac structure and function in patients with heart failure with reduced ejection fraction","volume":"322","author":"Januzzi","year":"2019","journal-title":"JAMA"},{"key":"2026010913041688500_ejhf3129-bib-0041","doi-asserted-by":"crossref","first-page":"1077","DOI":"10.1001\/jama.2019.12843","article-title":"Effect of sacubitril-valsartan vs enalapril on aortic stiffness in patients with heart failure and reduced ejection fraction: A randomized clinical trial","volume":"322","author":"Desai","year":"2019","journal-title":"JAMA"}],"container-title":["European Journal of Heart Failure"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/eurjhf\/article-pdf\/26\/2\/373\/65513821\/eurjhf_26_2_373.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/eurjhf\/article-pdf\/26\/2\/373\/65513821\/eurjhf_26_2_373.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,9]],"date-time":"2026-01-09T18:05:01Z","timestamp":1767981901000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/eurjhf\/article\/26\/2\/373\/8326963"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1,18]]},"references-count":41,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2024,1,18]]},"published-print":{"date-parts":[[2024,2,1]]}},"URL":"https:\/\/doi.org\/10.1002\/ejhf.3129","relation":{},"ISSN":["1388-9842","1879-0844"],"issn-type":[{"value":"1388-9842","type":"print"},{"value":"1879-0844","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2024,2]]},"published":{"date-parts":[[2024,1,18]]},"assertion":[{"value":"2023-09-26","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-12-26","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-01-18","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}